Efficacy and tolerability of aliskiren 300mg/hydrochlorothiazide 25mg (±amlodipine 5mg) in hypertensive patients not controlled by candesartan 32mg plus HCT 25mg

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 131-140

  Schweizer, Johannes ^a   Ulmer, Hans Joachim ^b   Benduhn, Henning ^b   Klebs, Sven ^c  

^a KLINIKUM CHEMNITZ   (Germany)

^b Practice for Internal Medicine   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Aliskiren; Amlodipine; Arterial hypertension; Candesartan; Combination therapy; Hydrochlorothiazide

Indexed keywords

ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; CANDESARTAN; HYDROCHLOROTHIAZIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; ICHTHYOSIS; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SELECTION; SIDE EFFECT; TREATMENT DURATION; VERTIGO;

ADULT; AGED; ALGORITHMS; AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78650339358     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.537318     Document Type: Article

References (30)

1. World Health Organization. Cardiovascular disease factsheet. Available at http://www.who.int/mediacentre/factsheets/fs317/en/index.html [Last accessed 18 November 2010]
2. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004; 22:479-86
3. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
4. Costanzo S, Di Castelnuovo A, Zito F, et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction - the impact of migration as a model of gene-environment interaction project. J Hypertens 2008;26:2303-11
5. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27
6. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
7. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906
8. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
9. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlo-dipine: the VALUE randomised trial. Lancet 2004;363:2022-31
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
11. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71
12. Chrysant SG. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2008;6:305-14
13. European Medicines Agency (EMA). Rasilez HCT(R) Aliskiren/hydrochlorothi- azide (manufacturer: Novartis). Product information. Available at: http:// www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 000964/WC500047220.pdf [Last accessed 14 October 2010]
14. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
15. European Medicines Agency (EMA). Exforge HCT(R) Amlodipine besylate/val-sartan/hydrochlorothiazide (manufacturer Novartis). Summary of Product Characteristics (SmPC). Last update 16 August 2010. Available at: http:// www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001068/WC500033641.pdf [Last accessed 14 October 2010]
16. Food and Drug Administration (FDA). Tribenzor (TM) Olmesartan medoxomil amlodipine besylate and hydrochlorothiazide (manufacturer Daiichi Sankyo). Product information dated 23 July 2010. Available at http://www.accessda-ta.fda. gov/drugsatfda-docs/label/2010/200175s000lbl.pdf [Last accessed 14 October 2010]
17. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-61
18. Braun N, Ulmer HJ, Ansari A, et al. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Curr Med Res Opin 2009;25:421-30
19. Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008;25:399-411
20. Schweizer J, Hilsmann U, Neumann G, et al. Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32mg plus HCTZ 25 mg in free combination. Curr Med Res Opin 2007;23:2877-85
21. European Medicines Agency (EMA). Rasilez. Assessment Report: Scientific Discussion. Available at: http://www.ema.europa.eu/humandocs/Humans/ EPAR/rasilez/rasilez.htm [Last accessed 18 November 2010]
22. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20
23. Oparil S, Yarows SA, Patel S, et al. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007;370:1126-7
24. Krone W, Hanefeld M, Meyer HF, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2010 (published online 9 April 2010) DOI: jhh201038[pii] 10.1038/jhh.2010.38
25. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009;32: 1873-9
26. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(9 Suppl.):2-6
27. Calhoun DA. Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother 2009;10: 1869-74
28. Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264-77
29. European Medicines Agency (EMA). Atacand Plus (R). Candesartan cilexetil and hydrochlorothiazide (manufacturer: Astra Zeneca). 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Atacand-Plus-30/WC500093969.pdf [Last accessed 18 November 2010]
30. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51